azenosertib
azenosertib: sourced relationships with 1 company · 9 clinical trials tracked.
azenosertib evidence translation
What we can confirm
9 tracked trials
What it means
What to watch
Prepared research question
How could azenosertib → ZNTL affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence8 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Zentalis Pharmaceuticals, Inc. (ZNTL) Solid Tumor; Osteosarcoma; Uterine Serous Carcinoma | Phase 3 |
Clinical Trial Registry Records (9)
A Randomized, Open-Label Phase 3 Study of Azenosertib Versus Investigator's Choice of Chemotherapy in Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
Primary endpoint: Progression free survival (PFS) per RECIST v1.1 as assessed by Investigator
A Phase I/II Single-arm Trial of Azenosertib (ZN-c3) Combined With Carboplatin and Pembrolizumab in Patients With Metastatic Triple-negative Breast Cancer (ZAP-IT)
Primary endpoint: Number of Participants Experiencing Dose Limiting Toxicity (DLT)
A Phase 2 Open-Label, Multicenter Study To Evaluate Efficacy And Safety Of ZN-c3 In Subjects With High-Grade Serous Ovarian, Fallopian Tube, Or Primary Peritoneal Cancer (DENALI / ZN-c3-005 / GOG-3066)
Primary endpoint: Objective Response Rate (ORR) defined by RECIST v1.1 [Part 2]
A Phase 1/2 Dose-Escalation and Dose-Expansion Study of ZN-c3 in Combination With Niraparib and ZN-c3 Monotherapy in Subjects With Platinum-Resistant Ovarian Cancer
Primary endpoint: To investigate the safety and tolerability of ZN-c3 in combination with niraparib, including identification of the MTD and RP2D
A Phase 1/2 Dose Escalation and Dose Expansion Study of ZN-c3 in Combination With Gemcitabine in Adult and Pediatric Subjects With Relapsed or Refractory Osteosarcoma
Primary endpoint: Incidence of dose-limiting toxicities (DLT) in DLT evaluable subjects and the incidence and severity of adverse events.
A Phase 2 Open-Label, Multicenter Study to Evaluate Efficacy and Safety of ZN-c3 in Adult Women With Recurrent or Persistent Uterine Serous Carcinoma
Primary endpoint: Frequency and severity of TEAEs
A Phase 1b Study of ZN-c3 in Combination With Chemotherapy or Bevacizumab in Subjects With Ovarian, Peritoneal, or Fallopian Tube Cancer
Primary endpoint: Part 1: To investigate the safety and tolerability of azenosertib in combination with PLD, carboplatin, paclitaxel, or gemcitabine
A Phase 1 Study of ZN-c3 as a Single Agent in Subjects With Solid Tumors
Primary endpoint: Dose Escalation
A Window of Opportunity Strategy for Targeted Pathway Inhibition in Patients With Pancreatic Ductal Adenocarcinoma
Primary endpoint: Proportion of all pharmacodynamic feasibility-evaluable participants within a study arm that have a measurable change in post-treatment tumor biology from baseline
Frequently asked questions
Which companies have sourced relationships with azenosertib?
azenosertib has dated SEC/FDA relationship records for Zentalis Pharmaceuticals, Inc..
How many clinical trials involve azenosertib?
BioSniper tracks 9 clinical trials involving azenosertib.